This will expand access to Luminopia’s engaging, evidence-based treatment for children and allow more patients to benefit from its unique approach to treating amblyopia
Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced that Anthem Blue Cross and Blue Shield has approved its amblyopia treatment for coverage. Patients who meet Anthem’s criteria will now have Luminopia covered by their plan. This is a significant step forward in ensuring that more children nationwide can have access to this FDA-cleared treatment option for amblyopia.
Health Technology Insights: HighPeak Launches AI Platform for Predictive Healthcare Costs
Anthem is the second largest health plan in the U.S. and now their members with amblyopia will have the option to watch TV as treatment and benefit from Luminopia’s unique, dual-acting mechanism of action – an approach that differs from traditional therapies and one that can be easily incorporated into a child’s daily life.
“This coverage milestone brings us closer to our goal of helping as many amblyopia patients as we can,” said Scott Xiao, Luminopia’s Co-Founder and CEO. “We’re proud to be addressing a significant unmet need in amblyopia care by further increasing access to our unique and effective software-driven treatment that’s backed by strong clinical data and multiple FDA clearances.”
Health Technology Insights: Akumin Appoints Chief Medical Officer
Luminopia works differently than traditional amblyopia treatments such as eye-patching and blurring eye drops. Rather than blocking the stronger eye like traditional treatments, Luminopia uses a unique, binocular method that encourages both eyes to work together. Patients watch popular, kid-friendly TV shows inside a VR headset for one hour a day, six days a week, making the treatment more engaging and leading to approximately 94% of parents preferring Luminopia over eye-patching. Clinical trials demonstrated significant vision improvement in as little as four weeks, in both newly diagnosed patients and in children who had already tried traditional therapies.
“It is incredibly encouraging that an innovative treatment option like Luminopia has become more accessible to children,” said Dr. Derek Sprunger, Professor at Indiana University School of Medicine, Pediatric Ophthalmology & Strabismus. “We are witnessing a transformative moment in amblyopia care, with more children gaining access to a therapy that not only improves outcomes but is also enjoyable to use. This represents a crucial step toward fewer children being left at risk of permanent vision loss.”
This news underscores Luminopia’s continued momentum and arrived just a week after the U.S. Food & Drug Administration (FDA) cleared Luminopia’s treatment for patients aged 8 to 12 years, expanding its previous label from patients 4 to 7 years old to patients 4 to <13 years old.
Luminopia is being prescribed by physicians at top eye institutes, children’s hospitals and private practices across the U.S. Eye care professionals can prescribe through CoAssist Pharmacy.
Health Technology Insights: MyOme and Collective Health Partner to Expand Genome Access
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
